Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer

Abstract

A serine/threonine protein kinase, recognized as Glycogen Synthase Kinase-3 (GSK-3) is documented as a regulator of assorted cellular roles. GSK-3 phosphorylates and thereby controls the action of many physiologic, messengers, and membrane-bound structures. GSK-3α and GSK-3β are two vastly homologous forms of GSK-3 in mammals. Recent information has recommended that GSK-3β is a constructive controller of cancer cell proliferation and subsistence affords GSK-3β as a key target in cancer. GSK-3 is overexpressed in various tumor types including ovarian tumors. In human breast carcinoma, it has been revealed that overexpression of GSK-3β was linked with breast cancer patients. The inhibition of GSK-3 or inhibitors of GSK-3 is a promising therapeutic tactic to overcome breast and ovarian cancer. This article features an important aspect of inhibitors of Glycogen Synthase Kinase-3 as a new lead to treating Breast and Ovarian Cancer.

Prevention and treatment of natural products from Traditional Chinese Medicine in depression: Potential targets and mechanisms of action

“…Glycogen synthase kinase-3 is a highly conserved family of protein kinase that acts by phosphorylating amino acid residues of serine/threonine ( Panagi et al, 2020 ). GSK-3 is divided into two subtypes, GSK-3α and GSK-3β ( Chandra et al, 2021 ). Phosphorylation at ser21 of GSK-3α or ser9 of GSK-3β can significantly inhibit its activity.…”